Cancer Research and Treatment

Original Article

Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy: Seung Hyeun Lee, Sue In Choi, Ji Sung Lee, Chul Hwan Kim, Won Jai Jung, Eun Joo Lee, Kyung Hoon Min, Gyu Young Hur, Seung Heon Lee, Sung Yong Lee, Je Hyeong Kim, Sang Yeub Lee, Chol Shin, Jae Jeong Shim, Kyung Ho Kang, Kwang Ho In; Cancer Res Treat. 2017;49(1):141-149. Published online May 18, 2016; DOI: https://doi.org/10.4143/crt.2016.133

Purpose
Reactive oxygen species modulator 1 (Romo1) is a key mediator of intracellular reactive oxygen species production. However, examination of the clinical usefulness of Romo1 in cancers has been limited. We evaluated the association of Romo1 expression with clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
Materials and Methods
Romo1 expression in tumor tissue was examined by immunohistochemistry and evaluated by histological score. Survival analyses were performed according to Romo1 expression and the association between Romo1 expression and clinical parameters was evaluated.
Results
A total of 88 tumor specimens were analyzed. Significantly shorter median progression-free survival (PFS) was observed in the high Romo1 group compared with the low Romo1 group (4.5 months vs. 9.8 months, p < 0.001), and the median overall survival (OS) of the high Romo1 group was also significantly shorter than that of the low Romo1 group (8.4 months vs. 15.5 months, p < 0.001). Results of multivariate analyses showed significant association of high Romo1 expression with both poor PFS (hazard ratio [HR], 2.75; 95% confidence interval [CI], 1.71 to 4.44) and poor OS (HR, 3.99; 95% CI, 2.36 to 6.74). Results of the subgroup analysis showed a similar association regardless of tumor histology. Romo1 expression showed no association with any clinical parameter including age, sex, smoking status, stage, differentiation, or tumor histology.
Conclusion
Romo1 overexpression was associated with poor response to treatment and shorter survival in advanced NSCLC patients treated with platinum-based chemotherapy. Romo1 could be a potential adverse predictive marker in this setting.

Citations

Citations to this article as recorded by

Prognostic Impact of Reactive Oxygen Species Modulator 1 in Surgically Resected Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas
Tae-Woo Kim, Kiyong Na, Junyang Jung, Heejin Lim, Hyewon Seo, Seung Hyeun Lee
Oncology.2024; 102(11): 969. CrossRef
ROMO1 – a potential immunohistochemical prognostic marker for cancer development
Eva Tsoneva, Mariela B. Vasileva-Slaveva, Stoyan G. Kostov, Angel D. Yordanov
Oncologie.2023; 25(6): 753. CrossRef
Serum Reactive Oxygen Species Modulator 1 as a Novel Predictive Biomarker for Resected Lung Adenocarcinoma: A Retrospective Pilot Study
Boksoon Chang, In Kyung Hwang, Seung Hyeun Lee
OncoTargets and Therapy.2021; Volume 14: 5097. CrossRef
Overexpression of Reactive Oxygen Species Modulator 1 Predicts Unfavorable Clinical Outcome in EGFR-Mutant Lung Adenocarcinomas Treated With Targeted Therapy
Won Gun Kwack, Ji-Youn Sung, Seung Hyeun Lee
Frontiers in Oncology.2021;[Epub] CrossRef
Overexpression of reactive oxygen species modulator 1 is associated with advanced grades of bladder cancer
Hadi Ghasemi, Mohammad Amin Amini, Atefeh Pegah, Ebrahim Azizi, Heidar Tayebinia, Shima Khanverdilou, Seyed Habibollah Mousavibahar, Aida Alizamir
Molecular Biology Reports.2020; 47(9): 6497. CrossRef
Reactive Oxygen Species Modulator 1 is Associated with Poor Survival in Patients with Non-Small Cell Lung Cancer After Stereotactic Fractionated Radiosurgery: A Retrospective Pilot Study

Moonkyoo Kong, Ji-Youn Sung, Seung Hyeun Lee
OncoTargets and Therapy.2020; Volume 13: 8173. CrossRef
Reactive oxygen species modulator 1 expression predicts lymph node metastasis and survival in early-stage non-small cell lung cancer
Taehee Kim, Yoon Jin Cha, Ji Hyun Park, Arum Kim, Yong Jun Choi, Hye Jung Park, Jung Weon Lee
PLOS ONE.2020; 15(12): e0239670. CrossRef
Reactive Oxygen Species Modulator 1 (ROMO1), a New Potential Target for Cancer Diagnosis and Treatment
Mohammad Amin Amini, Seyed Saman Talebi, Jamshid Karimi
Chonnam Medical Journal.2019; 55(3): 136. CrossRef
Reactive oxygen species modulator 1 (Romo1) as a novel diagnostic marker for lung cancer-related malignant effusion
Seung Hyeun Lee, Myung Jae Park, Sue In Choi, Eun Joo Lee, Sang Yeub Lee, Kwang Ho In
Medicine.2017; 96(4): e5975. CrossRef

15,150 View
187 Download
11 Web of Science
9 Crossref

Case Report

Two Cases of Humoral Hypercalcemia of Malignancy in Metastatic Cholangiocarcinoma: Seungtaek Lim, Jungwoo Han, Kyeong Hye Park, Won Jai Jung, Yong Kang Lee, Ara Choi, Young Jae Kim, Jong-Chan Lee, Hye Jin Choi; Cancer Res Treat. 2013;45(2):145-149. Published online June 30, 2013; DOI: https://doi.org/10.4143/crt.2013.45.2.145

Abstract PDF PubReader ePub

Humoral hypercalcemia of malignancy (HHM) is rarely associated with cholangiocarcinoma (CC), and represents dismal prognosis. A 63-year-old male was admitted for evaluation of an intrahepatic mass. He was diagnosed with HHM associated with locally advanced CC. As the tumor responded to the concurrent chemoradiotherapy with capecitabine and cisplatin, serum calcium level was normalized. However, according to the disease progression, he suffered recurrence of HHM and he expired approximately one year after initial diagnosis. A 68-year-old male who presented with abdominal pain was diagnosed with metastatic CC. After the eighth cycle of gemcitabine and cisplatin, progression of the disease was found with HHM. He was treated with the best supportive care, until his demise approximately one month after the diagnosis of HHM. We report on two cases of HHM associated with CC that demonstrate strong correlation between hypercalcemia and disease burden.

Citations

Citations to this article as recorded by

The peculiar clinical presentation and diagnostic results of a case of widely metastatic cholangiocellular carcinoma in a Siberian Husky dog
Hannah Reichert, Alexandra Macleod, Leslie Sharkey, Cornelia Peterson
Topics in Companion Animal Medicine.2024; 63: 100923. CrossRef
Prevalence and Clinicopathologic Characteristics of Hypercalcemia in Patients With Cholangiocarcinoma
Eirini Konstantinidou, Jordan R. Maurer, Stephanie L. Reyes, Islam Baiev, Jennifer R. Stanton, Ryan D. Nipp, Lipika Goyal
JAMA Oncology.2023; 9(5): 714. CrossRef
Recurrent distal cholangiocarcinoma and humoral hypercalcemia of malignancy: report of a rare case and literature review
Jun Ito, Kiten Sakai, Yuki Yamamoto, Rikako Nakajima, Kei Ito, Masanao Fujii, Hideki Matsumura, Norio Takayashiki, Masanao Kurata, Satoshi Inagawa, Hiroaki Yagyu
Endocrine Journal.2023; 70(4): 375. CrossRef
Hypercalcemia of Malignancy in a Dog Diagnosed With Cholangiocellular Carcinoma
Laura Martínez-Sogues, Anna Vila, Xavier Roura, Josep Pastor, Rosa Novellas, Alberto Marco, Maria Cuvertoret-Sanz, Jorge Martínez, Laia Solano-Gallego
Topics in Companion Animal Medicine.2019; 35: 1. CrossRef
Combined Hepatocholangiocarcinoma Associated with Humoral Hypercalcemia of Malignancy and Chronic Inflammatory Demyelinating Polyneuropathy
Ruben Manuel Luciano Colunga Biancatelli, Marco Ciacciarelli, Alessandro Polidoro, Piera Clemenzi, Viviana Congedo, Leonardo Calvosa, Eleonora D’Armiento, Carmen Misurale, Davide Bellini, Stefano Badia, Massimiliano Mancini, Vincenzo Petrozza, Luigi Iulia
Case Reports in Oncological Medicine.2019; 2019: 1. CrossRef
Humoral Hypercalcemia in a Patient with Cholangiocellular Carcinoma – Effective Therapy with Denosumab
Igor Alexander Harsch, Peter Christopher Konturek
American Journal of Case Reports.2019; 20: 1325. CrossRef
Humoral Hypercalcemia of Malignancy with a Parathyroid Hormone-Related Peptide-Secreting Intrahepatic Cholangiocarcinoma Accompanied by a Gastric Cancer
Katsushi Takeda, Ryosuke Kimura, Nobuhiro Nishigaki, Shinya Sato, Asami Okamoto, Kumiko Watanabe, Sachie Yasui
Case Reports in Endocrinology.2017; 2017: 1. CrossRef
Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma
Norihiro Ashihara, Koji Nakajima, Yoshiyuki Nakamura, Mutsuhiro Kobayashi, Kumiko Shirahata, Chika Maeda, Takeshi Uehara, Daisuke Gomi, Nobuo Ito
Internal Medicine.2016; 55(23): 3453. CrossRef
Esophageal Cancer Initially Presenting as Severe Paraneoplastic Hypercalcemia Requiring Hemodialysis
Hye Shin Ahn, Jong Min Yun, Yeong Bok Lee, Yu Mi Ko, Jung Eun Lee, Hye Sung Won, Sung Soo Kim, Young Ok Kim
The Korean Journal of Gastroenterology.2015; 65(6): 361. CrossRef

17,286 View
68 Download
9 Crossref

First
Prev
Page of 1
Next
Last

Search